Nirmatrelvir Production Cost Reports

The report provides a detailed analysis essential for establishing a nirmatrelvir production plant. It encompasses all critical aspects necessary for nirmatrelvir production, including the cost of nirmatrelvir production, nirmatrelvir plant cost, nirmatrelvir production costs, and the overall nirmatrelvir production plant cost. Additionally, the study covers specific expenditures associated with setting up and operating a nirmatrelvir production plant. These encompass production processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.

Nirmatrelvir is an oral antiviral medication that is combined with ritonavir to treat mild-to-moderate SARS-CoV-2 in high-risk individuals. It is utilised in adults and children aged 12 years or older weighing at least 40 kg, particularly those who are not hospitalised or oxygen-dependent and begin treatment within five days of symptom onset. It stops the SARS-CoV-2 main protease enzyme, which is essential for viral replication, preventing the virus from multiplying inside cells, thereby reducing the risk of progression to severe disease, hospitalisation, or death. Its standard regimen involves two 150 mg nirmatrelvir tablets plus one 100 mg ritonavir tablet taken twice daily for five days. Its common side effects include metallic taste, diarrhoea, nausea, vomiting, headache, muscle aches, high blood pressure, etc.

The market for nirmatrelvir is fuelled by SARS-CoV-2 variant threats. The sustained demand for oral antivirals in high-risk populations and investments in production efficiency contribute to its market growth. The patent expirations, generic competition, newer therapies, and regulatory hurdles affect its market dynamics. The high API costs from specialised producers, supply chain reliance on a few manufacturers, and pricing pressures amid consolidation impact industrial nirmatrelvir procurement. Other factors like quality control for purity in protease inhibitor synthesis, and regional variations favouring North America and Europe for infrastructure, while Asia-Pacific grows via economic expansion boosts its market.

Raw Material for Nirmatrelvir Production

According to the nirmatrelvir production plant project report, the key raw materials used in the production of nirmatrelvir include L-tert-leucine and ethyl trifluoroacetate.

Production Process of Nirmatrelvir

The extensive nirmatrelvir production cost report consists of the following major industrial production process:

From L-tert-leucine and ethyl trifluoroacetate: The production process for Nirmatrelvir starts with L-tert-leucine. First, N-trifluoroacetylation occurs using ethyl trifluoroacetate under optimised conditions to form N-trifluoroacetyl-L-tert-leucine. After that, direct amide coupling of this acid with the primary amine of the bicyclic [3.1.0]proline moiety to yield nirmatrelvir as the final product.

Nirmatrelvir is a white to off-white solid antiviral drug with molecular formula C₂₃H₃₂F₃N₅O₄, molecular weight 499.53 g/mol. It has a bicyclic [3.1.0]proline core, trifluoroacetamide, and nitrile warhead for covalent Mpro inhibition. It has moderate lipophilicity with a logP value of 2.2. It has low water solubility, requiring formulation as MTBE solvate or anhydrous Form 1 for oral tablets. It has a melting point of around 193 degree Celsius. It shows stability in room-temperature storage in Paxlovid combinations, with poor systemic absorption until boosted by ritonavir. All these physical and chemical properties makes it useful as an oral antiviral medication.